What if NAD+ depletion isn't the problem? What if it's the solution to something far worse?

Here's what's been nagging me. SIRT6 doesn't just regulate metabolism and DNA repair—it's also the primary suppressor of L1 retrotransposons. Those ancient viral sequences that litter our genome, waiting to copy and paste themselves into new chromosomal locations. And here's the kicker: SIRT6's occupancy at L1 loci is NAD+-dependent, but it follows a paradoxical allocation logic. When NAD+ is scarce, SIRT6 prioritizes retrotransposon silencing over other chromatin targets. When NAD+ is abundant, SIRT6 redistributes to metabolic gene promoters, histone deacetylation sites, telomeric regions—everywhere except the transposons.

So cellular NAD+ decline with age might not be dysfunction. It might be scarcity-mediated triage. The cell is deliberately starving itself to keep SIRT6 parked at those L1 elements. Because if they mobilize in post-mitotic neurons? We already know what happens. LINE-1 hypomethylation and retrotransposition correlate with neuronal death in Alzheimer's, ALS, and normal cognitive aging.

Now layer this on the NMN/NR supplementation data. We see methylome improvements, mitochondrial function increases, muscle performance gains—all real, all measurable. But has anyone done systematic L1 activity profiling in humans taking gram-level NAD+ precursors for years? The animal data is suggestive: p53-null mice with elevated NAD+ show increased retrotransposition. Aged mouse brains with exogenous NMN show improved metabolic markers but uncharacterized transposon expression.

We're boosting a cofactor without mapping what it unlocks.

The uncomfortable framing: aging might be a controlled descent where NAD+ restriction serves as a genomic containment mechanism. Forcing NAD+ back up could be opening a valve we closed for good reason. The longevity gains we measure might be real but shadowed by retrotransposition damage that manifests on a slower timescale—think decade-long latency, not months.

This needs serious funding. We need longitudinal studies pairing NAD+ precursor supplementation with L1 sequencing, single-cell retrotransposition mapping in aged human tissue, and honest reporting of transposon activation rates alongside the metabolic benefits we already celebrate.

Are we propping up a failing house of cards? Or worse—releasing what the house was built to contain?